Ainos Inc (AIMD)

[Monksdream]

AIMD new 52 week low

[Bigguy4]

If this selling doesn't stop , this company will lose its nasdaq listing . Then we all will be screwed .

[Awl416]

Wild

[subslover]

nope

[DK11]

Subs do you belong to WeBull?

[DK11]

Sorry, Bud this train is going nowhere for today.

[subslover]

I'm out last night @ $1.60 for a quick 100%

[Invest-in-America]

AIMD: Let's go!!



PS: I'm in @FREQ too today; could be a decent one. (Trying to curtail my traditional childish posting.)

[harry crumb]

Typical pump up an premarket selloff, careful here, it’l go go down to the .70’s again, they all do

[AJ Freely]

$AIMD - Up 76% Pre-Market/ Current Price $1.30
Company ramping up marketing of VELDONA® Pet & aiming to complete clinical trials in Taiwan of its flagship AI Nose-powered POCT by end of '23

[Monksdream]

Ainos Inc NASDAQ: AIMD*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap GrowthCompany profile
Ainos, Inc. is engaged in developing medical technologies for point-of-care (POCT) testing and medical treatment for a range of disease indications. The Company is engaged in the research and clinical development activities for its programs, securing related intellectual property, and commercializing therapeutics using low-dose non-injectable interferon (IFN). Its Medtech solutions includes COVID-19 Antigen Rapid Test Kit, Volatile Organic Compounds (VOC) POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha (VELDONA) and Synthetic RNA (SRNA). Its Ainos Flora device is intended to perform a non-invasive test for female vaginal health and certain common sexually transmitted diseases (STDs). Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia.

[subslover]

It pays to buy the best.

[Triple nickle]

Now we’re talkin

[subslover]

Huge gains today on 51 million shares traded.

[subslover]

Here ya go === https://www.streetinsider.com/Corporate+News/Ainos+%28AIMD%29%2C+Merdury+Sign+MoU+to+Explore+Phase+3+Study+of+VELDONA+Drug+Candidate+for+Treatment+of+Oral+Warts+in+HIV-Seropositive+Patients/21366603.html

[Awl416]

News?

[Invest-in-America]

THANKS AGAIN, T-B-T-9460!!

[TommyBoyTrader9460]

$AIMD Strong bottom bounce here..and check out that gap to will..adding to my watchlist for next week..

https://stockcharts.com/c-sc/sc?s=AIMD&p=D&b=5&g=0&i=0&r=1664637452592

[subslover]

Any time bro!

[Invest-in-America]

THANKS!!!

[subslover]

Ainos announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2. The company’s results showed that its low-dose oral interferon alpha (“IFN-a”) formulation, VELDONA, had a therapeutic effect on lungs infected with the SARS-CoV-2 (the Omicron variant) virus by regulating the immune response, thus expediting recovery of infected animals. Plus the company has submitted the application documents for U.S. FDA Phase 2 clinical trials for evaluating the efficacy of VELDONA in patients with mild COVID-19.

The study evaluated the effectiveness of VELDONA over a 16-day course (5-day pre-treatment, one-day during viral infection and ten-day treatment after infection) of Omicron-variant-infected hamsters. Compared with hamsters in the placebo group receiving solution without VELDONA (the Placebo Group), the hamsters in the group receiving solution with VELDONA demonstrated resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days. The body weights of the hamsters in the VELDONA Group remained more stable than those of the hamsters in the Placebo Group during the treatment period.

[Invest-in-America]

THOSE WARRANTS: Lord EZ!! I grabbed $5K worth at $0.48 this morning --- circa 10:00 a.m. (ET); heck, just a 'Lotto' play, from YOUR perspective! However, neither the Markets, nor my E-Turd acct., are displaying any 'increase', per se, in PRICE of my WARRANTS thereof. WEIRD!!

[makinezmoney]

$AIMDW: Woahhhhhhhhhhh.............. how many you get amigo ????

Howd I miss this ??

You are scaring me with all your early watches


Awesome stuff



GO $AIMDW

[Invest-in-America]

AIMDW: Hey, but watch its WARRANTS, Buckos!!! (HA-HA!!) Just might SPOOK-ya!!!

[Renee]

AIMD moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

AIMD one for 15 reverse split. PPS closed at .72

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Renee]

Amarillo Biosciences Inc., AMAR, changed to AINOS Inc., AIMD:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Alpine600]

I see that company name change is already reflected on my brokerage account and I now hold Ainos Inc. If you haven’t already checked out their website it’s worth a look. They are a subsidiary of Taiwan Carbon Nano Technology Corp. From a corporate governance and operations standpoint this represents a big improvement in my view. I had kind of written this investment off (long term holder) but I’m actually pretty excited again about potential.

[ANTI-BAGHOLDER]

This could be pretty big!

[ANTI-BAGHOLDER]

AMAR interesting news Change of control

https://www.accesswire.com/641597/Amarillo-Biosciences-Inc-Announced-Closing-under-Securities-Purchase-Agreement-with-Majority-Investor-and-Name-Change-to-Ainos-Inc

[MADDSTACKER]

Sorry that was total owned ..

[MADDSTACKER]

Insiders buying 150 k in stock

[GreenKnight]

This thing is going to fly. $AMAR

[adijas]

Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board

Amarillo, TX, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University of Western Australia and renown pioneer in interferon research, to the Company’s Scientific Advisory Board.

Based on the Company’s past successful clinical research using low-dose interferon, Dr. Beilharz will work closely with ABI and its research collaborators in initiating several clinical trials this year. These trials will primarily be focused on developing a therapeutic for COVID-19, as well as the continuation of the Company’s late-stage treatments for thrombocytopenia and Sjögren’s syndrome. ABI Chairman & CEO, Dr. Stephen T. Chen, remarked, “We are excited to be working again with Dr. Beilharz who has contributed tremendously to the interferon research field and there is a high degree of confidence that our non-injectable interferon development program, Veldona, will prove to be an effective therapeutic for these targeted indications based on supporting clinical research.”

In relation to COVID-19, clinical data has shown low-dose interferon alpha effective against other coronaviruses such as H1N1 and SARS. Previously, a published study for a collaborative phase 2b influenza trial conducted by Dr. Beilharz, “Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an in?uenza pandemic year” demonstrated 150 IU interferon alpha delivered orally with ABI’s proprietary formulated Veldona lozenge significantly reduced the severity of symptoms in males aged 50 years or more and showed potential to enhance vaccine-induced protection against influenza. Other published clinical and non-clinical studies confirm low-dose interferon’s unique mechanism of action provide the medical-scientific rationale for ABI’s clinical development strategy for Veldona. Applying clinical studies towards COVID-19 is a logical next step.

Dr. Beilharz has stated, “The current COVID-19 pandemic urgently requires prevention and treatment options, particularly for frontline medical staff and at-risk groups, and oral low-dose type 1 interferon is a readily available public health option with an extensive published literature. It’s exciting that in the Hubei Province in China, where this pandemic originated, they have released details of a study where they treated over 2,000 frontline medical workers with oral interferon nose drops to try and protect them. There have been no reports of any contracting COVID-19, while in the controls - another 2,000 nurses and doctors working in the same province - 50 to 60 per cent were infected with COVID-19. That is a pretty clear demonstration of the prophylactic value of this.” Dr. Beilharz will be managing the Company’s COVID-19 clinical trials in Australia.

ABI is also preparing to resume its clinical trials for thrombocytopenia, an immune condition causing low platelet count prevalent in patients that experience hepatitis-C relapse and other debilitating conditions such as chemotherapy treatment. In a 2014 published study, “A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse,” Dr. Chau-Ting Yeh, Director, Liver Research Center at Chang Gung Memorial Hospital (Taiwan), was the co-author and principal investigator for a phase 2 clinical trial in which it was discovered that 500 IU low-dose interferon alpha was surprisingly effective in exerting a significantly expedited recovery of platelet count in chronic hepatitis C patients having moderate to severe liver fibrosis. As a result of this study ABI applied for and received four thrombocytopenia related patents. Dr. Yeh will be managing the Company’s subsequent thrombocytopenia clinical trials in Taiwan.

“As we move forward with planned Veldona clinical trials, both Dr. Beilharz and Dr. Yeh’s decades of research experience will be critical in successful execution and the establishment of effective collaborations with other stakeholders. Our goal will be to diligently advance the Veldona clinical trial program with the vision of developing Veldona-based new treatments for COVID-19 patients, as well as patients with difficult-to-treat indications like thrombocytopenia and autoimmune disorders such as Sjögren’s syndrome who are in urgent need for therapeutic solutions,” said Dr. Stephen T. Chen.

About Dr. Manfred Beilharz

A leader in interferon research, Dr. Beilharz has extensive knowledge of type-1 interferons in relation to diseases of viral, autoimmune and neoplastic origin, as well as principal investigator experience in numerous interferon research studies including previous collaboration with ABI in an oral low-dose interferon alpha “Winter Colds and Flu” phase IIb clinical trial in Perth, Western Australia (2008-2010). Dr. Beilharz serves on the scientific advisory boards of US and Australian Biotech companies, consults widely, and is on the editorial board of the “Journal of Interferon and Cytokine Research.” He has worked full time in biomedical research since 1982 holding posts at Monash University, the University of Western Australia, Johns Hopkins University, Oxford University and the Australian Neuromuscular Research Institute.

About Dr. Chau-Ting Yeh

Dr. Yeh is currently a Director of the Liver Research Center at Chang Gung Memorial Hospital and is a leading researcher in hepatology with extensive experience in molecular biology and treatment of hepatitis B and hepatitis C, Hepatocarcinogenesis and marker-guided anticancer treatment. His ground-breaking research publication “Efficacy of Low Dose Oral Interferon-alpha in Preventing Hepatitis C Relapse” was instrumental in ABI obtaining its current patents related to thrombocytopenia. Dr. Yeh has an M.D. from National Taiwan University, Medical School and Ph.D. from USC, Department of Internal Molecular Microbiology and Immunology. He has received numerous awards including Distinguished Research Faculty Member, Chang Gung University (2012) and Taiwan Ministry of Science & Technology, FutureTech Demo and Breakthrough Award (2019).

[GreenKnight]

$AMAR - I like this - https://www.globenewswire.com/news-release/2020/09/10/2092023/0/en/Amarillo-Biosciences-to-Initiate-Low-Dose-Interferon-Clinical-Trials-to-Treat-COVID-19-Appoints-Interferon-Specialist-Dr-Manfred-Beilharz-to-Scientific-Advisory-Board.html

[Quintessence]

Another Form 4.

[Quintessence]

Several form 4s out recently. Hoping PPS can move up from here.

[willlbone]

Guillotine goes chop.

[InforichIH]

Press Release
Amarillo Biosciences, Inc. Receives Approval of Patent Claims - Treatment of Thrombocytopenia Using Orally Administered Interferon

Published: Oct 6, 2016 9:32 a.m. ET

Oct 06, 2016 (ACCESSWIRE via COMTEX) -- AMARILLO, TX / ACCESSWIRE / October 6, 2016 / Amarillo Biosciences, Inc. (ABI) AMAR, +15.20% today announced that eight claims of its latest patent application, which apply the use of low-dose oral interferon to the reversal of Thrombocytopenia, have been allowed by the U.S. Patent & Trademark Office. The patent is expected to issue before year end, 2016. ABI has full rights to exploit this patent in the U.S., Africa, India, Thailand, Malaysia, Australia, New Zealand, Indonesia, the Philippines, and certain other smaller markets.

"Approval of this patent signifies a very important milestone for ABI and for medicine," said Dr. Stephen T. Chen, Chairman and CEO of the Company. "Low dose oral interferon has been proven to be extremely safe for human therapies. Furthermore, our low-dose oral interferon has shown very positive results in various clinical trials. Issuance of this patent will expedite the development and commercialization of the new treatment and usher the product into global markets."

Thrombocytopenia is a blood system disorder in which there is a reduction in the thrombocyte (platelet) count caused by suppression of bone marrow, the blood-producing organs. The use of high-dose injectable interferon, chemotherapies, nonsteroidal anti-inflammatory drugs (NSAIDs), penicillin, antibiotics and other strong, harsh medicines used in the treatment of diseases and chronic conditions, cause such an effect on the bone marrow and platelets. Platelets play the key role in the formation of blood clots which prevent and stop hemorrhage (uncontrolled bleeding) from a ruptured or injured blood vessel. Thrombocytopenia increases the risk of spontaneous bleeding, which could become fatal if it occurs in the head (intracranial areas) or from the lining of the stomach or somewhere else in the gastrointestinal system.

Although not yet approved by U.S. FDA, ABI believes that low-dose oral interferon will prove to be a safe and affordable treatment for people with severe or life-threatening thrombocytopenia. Current treatments are effective but expensive and come with serious side effects and surgical risks. Such treatments include Immunoglobulin therapy (IVIG) given through a vein, plasma exchange (plasmapheresis), platelet transfusions, and corticosteroid medicine.

The scientific proof for this patent came out of a clinical trial conducted in Taiwan between 2009 and 2012. This trial was designed to use low dose oral interferon to help prevent viral recurrence in hepatitis C patients who have received the combination conventional therapy - high-dose injectable interferon-a and ribavirin. As a result of receiving this therapy, numerous patients suffered thrombocytopenia. Surprisingly, platelet counts of one treatment group, in which patients received 500IU of low dose oral interferon daily, quickly recovered back to the normal range within 4 weeks and the patients experienced almost no adverse side effects. The results were highly statistically significant (p = 0.003).

"ABI is very confident that low dose oral interferon will prove to be far superior to those thrombocytopenia drugs currently on the market. We are actively seeking partnerships in future development opportunities," added Dr. Chen.

About Amarillo Biosciences, Inc. (www.amarbio.com)

Amarillo Biosciences, Inc. (ABI) is a Texas corporation formed in 1984 that engaged in developing biologics for the treatment of human and animal diseases. Such human disease research includes influenza, hepatitis C, Chronic Cough in COPD, thrombocytopenia caused by other diseases and as a side effect of treatment of other diseases, and other disease indications using natural human interferon alpha that is administered in a proprietary low dose oral form. ABI has conducted more than 100 pre-clinical (animal) and human studies on the safety and efficacy of low-dose orally administered interferon. The Company is aggressively seeking partners with which to build relationships for new areas of discovery and expansion.

The Company has reorganized and restructured into three business units: the Medical, Pharmaceutical, and Consumer Product Divisions. These divisions will serve to create multiple revenue streams through the implementation of programs (including but not limited to in-licensing) of novel medical and health care products and processes. The overall operating strategy is for ABI to create a world-wide network of strategic alliances capitalizing on advanced and emerging technologies in order to engineer a diversified enterprise having a major impact on every aspect of the healthcare and life sciences industries. In addition, assemble an exhaustive pipeline of technologically-advanced, cutting edge products and services with which to compete in the American and Asian markets.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates (including geographic placement of products) and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Investor Relations: Bernard Cohen

Amarillo Biosciences, Inc. Tel: [phone] Extension 16

Fax: [phone]

E-mail: [e-mail]

SOURCE: Amarillo Biosciences, Inc.

http://www.accesswire.com/img.ashx?id=446587

Copyright 2016 ACCESSWIRE

Noticed this was not posted here. A bit dated but potentially significant. The principal investors in AMAR are holding and still buying, so we will see what develops in future months. Time to watch and wait; no need to hyperventilate and pump.

[Renee]

AMARQ: Emerged from Bankruptcy. 1-19 R/S pursuant to the Plan of Reorganization. New Symbol: AMARD

http://otce.finra.org/DailyList

[Mm26]

Thanks drug man for great info.

[drugmanrx]

Form 8-K for AMARILLO BIOSCIENCES INC

27-May-2014

Bankruptcy or Receivership


Item 1.03. Bankruptcy or Receivership

On May 20, 2014, the Honorable Robert L. Jones, United States Bankruptcy Judge, in the Court's Amarillo Division, 624 S. Polk, Suite 100, Amarillo, Texas 79101-2389, heard the evidence and arguments of counsel regarding confirmation of Debtor's Plan of Reorganization, filed February 21, 2014 ("the Plan") (Doc. No. 110). By order dated March 23, 2014 by Judge Jones, it was ordered that:
1. The Plan of Reorganization filed by the Debtor on February 21, 2014, is CONFIRMED.
2. Except for the new debts and obligations of Debtor provided for by the Plan, Debtor is discharged and released from all claims and debts in accordance with 11 U.S.C. ? 1141.
3. Except as otherwise provided in the Plan, the property dealt with by the Plan is free and clear of all claims and interests of creditors and equity security holders, and all property and assets of the Debtor shall vest in the reorganized debtor (in the Plan, "New ABI") which may thereafter operate its business free of any restrictions imposed by the Code.
4. Except as specifically provided by the Plan or any approved modification of or amendment to the Plan, ALL CREDITORS, INTEREST HOLDERS, AND OTHER PARTIES IN INTEREST ARE PERMANENTLY ENJOINED ON AND AFTER THE EFFECTIVE DATE OF THE PLAN OF REORGANIZATION FROM: (a) commencing or continuing in any manner any actions or other proceedings of any kind with respect to any pre-petition claim or interest against the Debtor, (b) enforcing, attaching, collecting or recovering by any manner or means any judgment, award, decree or Order against the Debtor or against property of the Debtor regarding any such claim or interest, (c) creating, perfecting, or enforcing any encumbrance of any kind against the Debtor or against property of the Debtor with respect to any such claim or interest, and (d) asserting any set off, right of subrogation, or recoupment of any kind against any obligation owing to the Debtor, with respect to any such claim or interest.
5. As of the Effective Date of the Plan, the Official Committee of Equity Security Holders ("the Committee") will be dissolved, and its members are discharged and released from any further duties as an official committee under the Code. No professional persons were retained by the Committee, so no fees or expenses are allowed for any Committee professionals.
6. The following persons have timely exercised election to be treated under Class 5 (Administrative Convenience):
? Joel Michalek

? Prelude Dynamics

? Chrystal Shelton

? Goldstar Protective Services

? Johnson & Sheldon, P.C.

? American Stock Transfer

7. Upon entry of this Order, the Debtor is authorized and directed to take all steps necessary and appropriate to implement the Plan without the need for further shareholder, director, or other corporate approvals or action, including without limitation, the issuance of new equity securities to the Yang Group and the implementation of the reverse stock split specified in the Plan.
8. The Second Interim Order Establishing Procedures for Certain Transfers of Debtor's Common Stock (Doc No. 138) remains in full force and effect through and until the Effective Date of the Plan, at which time it will terminate.
9. The 14-day stay of this Order imposed by Bankruptcy Rule 3020(e) 1 shall not apply, and this Order is effective upon entry. Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

AMARILLO BIOSCIENCES, INC.

Date: May 27, 2014 By: /s/ Stephen T. Chen Stephen T. Chen, Chairman of the Board, and Chief Executive Officer

1 Or Bankruptcy Rule 6004(h) or (d), as applicable.

[Mm26]

Anyone know what happend to chapter 11 filings?is the company still exists?

[Sage7243]

Saw this on Gold Medal Stocks. So nice of them to promote a stock that was headed into bankruptcy.

[fast.money]

that's all

[kura]

I sent two different emails in two email account, but says mail delivery problem. Looks like email is no longer valid. Do you have any new contact?

Thanks
Amar

[knrorrel]

AMARQ NOW # 11 and 595 % http://investorshub.advfn.com/boards/breakoutboards.aspx

[knrorrel]

AMARQ TODAY UP TO 0,05 + $$$$$$ AMARQ IS HOT AND WILL GO UP $$$$

[Zer0Veritas]

Does AMARQ have any pending pdufa dates or pending trials for fda approval?

[OTCdoc]

is there still something left in the tank here tomarrow ? going up ?